obesity

[Scientific Reports] Scientists evaluated changes in urea cycle enzymes in non-alcoholic fatty liver disease (NAFLD) patients and in two preclinical animal models mimicking this entity. Seventeen liver specimens from NAFLD patients were included for immunohistochemistry and gene expression analysis.

[Nature Communications] Targeting Mat1a activated the liver-brown adipose tissue axis by increasing NRF2-mediated FGF21 secretion, which prevented obesity, insulin resistance and hepatosteatosis.

[Free Radical Biology and Medicine] Researchers investigated whether peri-pancreatic white adipose tissue produced oxygenated lipids, namely isoprostanes and neuroprostanes and whether they can influence β-cell function in obesity.

[Acta Pharmacologica Sinica] Scientists discuss potential strategies for developing future therapeutic farnesoid-X-receptor (FXR) modulators to overcome current limitations for fibrosis diseases, providing new perspectives for enterohepatic and metabolic diseases treatment.

[Acta Pharmacologica Sinica] Scientists summarize the current knowledge on the role of bile acids and the receptors in the development of nonalcoholic fatty liver disease and nnonalcoholic steatohepatitis, especially the functions of farnesoid X receptor in different tissues including liver and intestine.

[Molecular Medicine Reports] Protein expression was detected by western blotting. Cell Counting Kit‑8 assays were performed to analyze cell viability, and flow cytometry and a TUNEL assay was performed to evaluate cell apoptosis.